First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study
2015
To assess the safety, tolerability, pharmacokinetics, and
pharmacodynamicsof the Fc-inactivated anti-β amyloid (Aβ) monoclonal antibody (mAb) GSK933776 in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Keywords:
-
Correction
-
Source
-
Cite
-
Save
18
References
19
Citations
NaN
KQI